Action of Recombinant Interferons and Interleukin 2 in Modulating Radiation Effects on Viability and Cytotoxicity of Large Granular Lymphocytes

References

• Aaran R.K., Hietanen T., Pitkänen M., Leinikki P. Comparison of ATP measurement with bioluminescence, trypan blue exclusion and 51Cr-release assay in irradiated NK cells. 10th International Congress on Photobiology, Jerusalem, Israel, Book of Abstracts. 1988; 15–15
   Google Scholar
• Altman K.I., Gerber G.B., Okada S. Radiation Biochemistry. Academic, New York 1970; I: 257–258, 2 vols Vol II., p. 49.
   Google Scholar
• Bandyopathyay S., Miller D.S., Matsumoto-Kobayashi M., Clarck S.C., Starr S.E. Effects of interferons and interleukin 2 on natural killing of cytomegalovirus-infected fibroblasts. Clinical and Experimental Immunology 1987; 67: 372–382
   PubMed Web of Science ®Google Scholar
• Broval C., Schacter B. Radiation sensitivity of human natural killer activity: control by X-linked genes. Journal of Immunology 1981; 126: 2236–2239
   PubMed Web of Science ®Google Scholar
• Cameron R.B., Spiess P.J., Rosenberg S.A. Synergistic antitumor activity of tumor infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Journal of Experimental Medicine 1990; 171: 249–263
   PubMed Web of Science ®Google Scholar
• Cohen A., Barankiewicz J. Metabolic consequences of DNA damage. Alteration in purine metabolism following Poly(ADP Ribosyl)ation in human T-lymphoblasts. Archives in Biochemistry and Biophysics 1987; 258: 498–503
   PubMed Web of Science ®Google Scholar
• Cohen J.J., Duce R.C., Chervenak R., Sellins K.S., Olson L.K. DNA fragmentation in targets of CTL: an example of programmed cell death in the immune system. Advances of Experimental and Medical Biology 1985; 184: 493–506
   PubMed Web of Science ®Google Scholar
• Gerber M., Guichard M., Pioch Y., Dubois J.B. The influence of Interleukin-2, feeder cells, and timing of irradiation on the radiosensitivity of human T lymphocytes assessed by the colony-forming assay. Radiation Research 1989; 120: 164–176
   PubMed Web of Science ®Google Scholar
• Gresser I., Maury C., Brouty-Boyé D. Mechanism of the antitumour effect of interferon in mice. Nature 1972; 239: 167–168
   PubMed Web of Science ®Google Scholar
• Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Journal of Experimental Medicine 1982; 155: 1823–1841
   PubMed Web of Science ®Google Scholar
• Gutterman J.U., Blumenschein G.R., Alexanian R., Yap H.Y., Buzdar A.U., Cabannilas F., Hortobagyi G.N., Hersh E.M., Rasmussen S.L., Harmon M., Kramer M., Petska S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Annals of Internal Medicine 1980; 93: 399–406
   PubMed Web of Science ®Google Scholar
• Hietanen T., Pitkänen M., Aaran R.-K., Leinikki P. Effect of fractionated radiation on viability and cytotoxicity of natural killer cells (NK cells). 22nd Annual Meeting of European Society for Radiation Biology, Brussels, Belgium, Book of Abstracts. 1989; 28–28
   Google Scholar
• Hietanen T., Pitkänen M., Aaran R.-K., Leinikki P. Interleukin 2 (IL-2) clearly reduces the effect of radiation on natural killer cells (NK cells): interferons are less active. Frontiers in Radiation Biology, E. Riklis. VCH, New York 1990; 77–82, In
   Google Scholar
• James S.E., Arlett C.F., Green M.H.L., Bridges B.A. Radiosensitivity of human T-lymphocytes proliferating in long term culture. International Journal of Radiation Biology 1983; 44: 417–422
   Web of Science ®Google Scholar
• Kangas L., Gronroos M., Nieminen A.-L. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Medical Biology 1984; 62: 338–343
   PubMedGoogle Scholar
• Kellerer A.M., Rossi H.H. The theory of dual radiation action. Current Topics of Radiation Research Quarterly 1972; 8: 85–158
   Google Scholar
• Kellerer A.M., Hug O. Theory of dose-effect relations. Encyclopedia of Medical Radiology, L. Diethelm, O. Olsson, F. Strnad, H. Vieten, A. Zuppinger. Springer, Berlin 1972; 1–42, In
   Google Scholar
• Kondrad M.W., Hemstreet G., Hersh E.M., Mansell P.W., Mertelsmann R., Kolitz J.E., Bradley E.C. Pharmakokinetics of recombinant interleukin 2 in humans. Cancer Research 1990; 50: 2009–2017
   PubMed Web of Science ®Google Scholar
• Merluzzi V.J., Savage D.M., Mertelsmann R., Welte K. Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2. Cellular Immunology 1984; 84: 74–84
   PubMed Web of Science ®Google Scholar
• Ortaldo J.R., Mantovani A., Hobbs D., Rubinstein M., Petska S., Herberman R.B. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. International Journal of Cancer 1983; 31: 285–289
   PubMed Web of Science ®Google Scholar
• Pross H.F., Baines M.G. Spontaneous human lymphocyte mediated cytotoxicity mediated against tumor target cells. I. The effect of malignant disease. International Journal of Cancer 1976; 18: 593–604
   PubMed Web of Science ®Google Scholar
• Puck T.T., Marcus P.L. Action of X-rays on mammalian cells. Journal of Experimental Medicine 1956; 103: 653–666
   PubMed Web of Science ®Google Scholar
• Rana R., Vitale M., Mazzoti G., Manzoli L., Papa S. Radiosensitivity of human natural killer cells: Binding and cytotoxic activities of natural killer cell subsets. Radiation Research 1990; 124: 96–102
   PubMed Web of Science ®Google Scholar
• Rinehart J.J., Malspeis L., Young D., Neidhart J.A. Phase I/II trial of human recombinant interferongamma in renal cell carcinoma. Journal of Biological Response Modifiers 1986a; 5: 300–308
   PubMedGoogle Scholar
• Rinehart J.J., Malspeis L., Young D., Neidhart J.A. Phase I/II trial of human recombinant-interferon serine in patients with renal cell carcinoma. Cancer Research 1986b; 46: 5364–5367
   PubMed Web of Science ®Google Scholar
• Robertson M.J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421–2438
   PubMed Web of Science ®Google Scholar
• Rosenberg S.A. Immunotherapy of cancer by systemic administration of lymphoid cells plus Interleukin-2. Journal of Biological Response Modifiers 1984; 3: 501–511
   PubMedGoogle Scholar
• Rotstein S., Baral E., Blomgren H., Johansson B. In vitro radiosensitivity of the spontaneous cytotoxicity of blood lymphocytes in patients with untreated Hodgkin's disease. European Journal of Cancer and Clinical Oncology 1983; 19: 1405–1409
   PubMedGoogle Scholar
• Saksela E., Timonen T., Cantel K. Human natural killer cell activity is augmented by interferon via recruitment of ‘pre-NK’ cells. Scandinavian Journal of Immunology 1979; 10: 257–266
   PubMed Web of Science ®Google Scholar
• Samid D., Flessate D.M., Friedman R.M. Interferon-induced revertants of ras-transformed cells: Resistance to transformation by specific oncogenes and retransformation by 5-azacytidine. Molecular and Cellular Biology 1987; 7: 2196–2200
   PubMed Web of Science ®Google Scholar
• Schacter B., Broval C., Pierce G., Ellner J. Non-specific cellular cytotoxicity differs from natural killer activity in its sensitivity to radiation. Immunobiology 1982; 163: 410–410
   Web of Science ®Google Scholar
• Silagi S., Dutkowski R., Schaefer A. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma. International Journal of Cancer 1988; 41: 315–322
   PubMed Web of Science ®Google Scholar
• Sone S., Utsugi T., Nii A., Ugura T. Differential effects of recombinant interferons, and on induction of human lymphokine (IL-2) activated killer activity. Journal of the National Cancer Institute 1988; 80: 425–431
   PubMed Web of Science ®Google Scholar
• Steineck G., Strander H., Carbin B.-E., Borgstrom E., Wallin L., Achtnich U., Arvidson A., Söderlund V., Näslund I., Esposti P.-L., Norell S.E. Recombinant leukocyte interferon alpha-2A and medroxy-progesterone in advanced renal cell carcinoma. Acta Oncologica 1990; 29: 155–162
   PubMed Web of Science ®Google Scholar
• Timonen T., Ortaldo J.R., Herberman R.B. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. Journal of Experimental Medicine 1981; 153: 569–582
   PubMed Web of Science ®Google Scholar
• Timonen T., Ortaldo J.R., Stadler B.M., Bonnard G.D., Sharrow S.O., Herberman R.B. Cultures of purified human natural killer cells: growth in presence of interleukin 2. Cellular Immunology 1982; 72: 178–185
   PubMed Web of Science ®Google Scholar
• Timonen T., Saksela E. Isolation of human NK cells by density gradient centrifugation. Journal of Immunological Methods 1980; 36: 285–291
   PubMed Web of Science ®Google Scholar
• Zarcone D., Tilden A.B., Vanessa G.L., Grossi C.E. Radiation sensitivity of resting and activated nonspecific cytotoxic cells of T lineage and NK lineage. Blood 1989; 73: 1615–1621
   PubMed Web of Science ®Google Scholar